Comparison of independent and combined metabolic effects of chronic treatment with ( pGlu ‐Gln)‐ CCK ‐8 and long‐acting GLP ‐1 and GIP mimetics in high fat‐fed mice
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Aim: The incretin hormones, glucagon‐like peptide‐1 ( GLP ‐1) and glucose‐dependent insulinotropic polypeptide ( GIP ) and cholecystokinin ( CCK ) are gastrointestinal peptides with important physiological effects. However, rapid enzymatic degradation results in short‐lived biological actions. Methods: This study has examined metabolic actions of exendin‐4, GIP [ mPEG ] and a novel CCK ‐8 analogue, ( pGlu ‐Gln)‐ CCK ‐8 as enzymatically stable forms of GLP ‐1, GIP and CCK , respectively. Results: All peptides significantly (p < 0.01–p < 0.001) stimulated insulin secretion from BRIN BD11 cells, and acute in vivo experiments confirmed prominent antihyperglycaemic and insulinotropic responses to GLP ‐1 or GIP receptor activation in normal mice. Twice daily injection of ( pGlu ‐Gln)‐ CCK ‐8 alone and in combination with exendin‐4 or GIP [ mPEG ] in high fat‐fed mice significantly decreased accumulated food intake (p < 0.05–p < 0.01), body weight gain (p < 0.05–p < 0.01) and improved (p < 0.05) insulin sensitivity in high fat‐fed mice. However, there was no evidence for superior effects compared to ( pGlu ‐Gln)‐ CCK ‐8 alone. Combined treatment of ( pGlu ‐Gln)‐ CCK ‐8 and exendin‐4 resulted in significantly (p < 0.05) lowered circulating glucose levels and improved (p < 0.05) intraperitoneal glucose tolerance. These effects were superior to either treatment regime alone but not associated with altered insulin concentrations. A single injection of ( pGlu ‐Gln)‐ CCK ‐8, or combined with exendin‐4, significantly (p < 0.05) lowered blood glucose levels 24 h post injection in untreated high fat‐fed mice. Conclusion: This study highlights the potential of ( pGlu ‐Gln)‐ CCK ‐8 alone and in combination with incretin hormones for the treatment of type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ahrén, B., Pettersson, M., Uvnäs-Moberg, K., Gutniak, M., & Efendic, S. (1991) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(91)90059-m · Cited by 50 · cited 1×
“However, CCK-8 is known to possess prominent insulin secretory effects and antidiabetic actions at pharmacological levels in man [22].”
Background
Cited by
Gault, V. A., Bhat, V. K., Irwin, N., & Flatt, P. R. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.512046 · Cited by 123
Self-citationEnteroendocrine hormone mimetics for the treatment of obesity and diabetes
Irwin, N., & Flatt, P. R. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.09.009 · Cited by 41
Self-citationHasib, A. (2020) · Clinical Medicine Insights: Endocrinology and Diabetes · doi:10.1177/1179551420905844 · Cited by 29
Metadata
- Authors
- Irwin, N., Hunter, K., Montgomery, I. A., & Flatt, P. R.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2013-02-26
- Volume
- 15
- Issue
- 7
- Pages
- 650-659
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2056299756
- Cited by
- 35
- References
- 1
- FWCI
- 2.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.